Conditions:   Bladder Cancer;   Cervical Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastrointestinal Complications;   Long-term Effects Secondary to Cancer Therapy in Adults;   Ovarian Cancer;   Prostate Cancer;   Radiation Toxicity;   Sarcoma;   Testicular Germ Cell Tumor;   Vaginal Cancer
Interventions:   Other: questionnaire administration;   Procedure: gastrointestinal complications management/prevention;   Procedure: quality-of-life assessment
Sponsor:   Royal Marsden NHS Foundation Trust
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: carboplatin;   Drug: oxaliplatin;   Drug: paclitaxel;   Procedure: quality-of-life assessment
Sponsor:   University College London Hospitals
Recruiting - verified March 2010

Conditions:   Ovarian Cancer;   Bowel Obstruction
Interventions:   Drug: Cisplatin;   Drug: Paclitaxel
Sponsor:   University Health Network, Toronto
Recruiting - verified February 2010

Conditions:   Cognitive/Functional Effects;   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: systemic chemotherapy;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: cognitive assessment;   Procedure: quality-of-life assessment
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Not yet recruiting - verified March 2010

Condition:   Ovarian Cancer
Interventions:   Drug: olaparib;   Drug: paclitaxel;   Drug: carboplatin
Sponsor:   AstraZeneca
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Not yet recruiting - verified February 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: pegfilgrastim;   Drug: bortezomib;   Drug: carboplatin;   Other: pharmacological study
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Not yet recruiting - verified February 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Sarcoma;   Ovarian Stromal Cancer;   Recurrent Cervical Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Uterine Sarcoma;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Stage III Cervical Cancer;   Stage III Endometrial Carcinoma;   Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage III Uterine Sarcoma;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Uterine Sarcoma;   Stage IV Vulvar Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer
Interventions:   Radiation: stereotactic radiosurgery;   Procedure: quality-of-life assessment
Sponsor:   Case Comprehensive Cancer Center
Recruiting - verified March 2010

Conditions:   Ovarian;   Breast;   Prostate;   Pancreatic;   Advanced Tumours
Intervention:   Drug: olaparib
Sponsor:   AstraZeneca
Recruiting - verified March 2010

Condition:   Infertility, Female
Intervention:  
Sponsor:   Hillel Yaffe Medical Center
Not yet recruiting - verified March 2010

Conditions:   Ovarian Cancer;   Non Small Cell Lung Cancer;   Prostate Cancer;   Colorectal Cancer;   Gastric Cancer;   Esophageal Cancer;   Cancer of Head and Neck
Intervention:   Drug: LY2523355
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified March 2010

Condition:   Polycystic Ovary Syndrome
Intervention:  
Sponsors:   Copenhagen University Hospital, Hvidovre;   Dpt. of endocrinology, Aarhus University Hospital;   Statens Serum Institute
Completed - verified January 2008

Condition:   Ovarian Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: carboplatin;   Drug: cisplatin;   Drug: etoposide phosphate;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Polycystic Ovary Syndrome
Intervention:   Behavioral: Nutrition Education, Dietary Counseling, and Cooking
Sponsors:   Children's Hospital Boston;   Thrasher Research Fund
Not yet recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: anti-HGF monoclonal antibody AMG 102;   Other: laboratory biomarker analysis
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Not yet recruiting - verified March 2010

Condition:   Polycystic Ovary Syndrome
Interventions:   Drug: Atorvastatin;   Drug: Placebo
Sponsors:   University of Oulu;   Pfizer
Recruiting - verified February 2010

Conditions:   Ovarian Cancer;   Peritoneal Cavity Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: ABT-888;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Suspended - verified March 2010

Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms
Interventions:   Drug: Placebo;   Drug: BIBF 1120
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Endometrial Cancer;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Liver Cancer;   Lung Cancer;   Ovarian Cancer
Interventions:   Biological: bevacizumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Metastatic Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Procedure: quality-of-life assessment
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Biological: allogeneic CMV/AdV-specific cytotoxic T lymphocytes;   Other: laboratory biomarker analysis
Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: belinostat;   Drug: carboplatin
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: ABT-888;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Epithelial Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions:   Drug: Paclical®;   Drug: Taxol®
Sponsors:   Oasmia Pharmaceutical AB;   Orion Corporation, Orion Pharma
Recruiting - verified February 2010

Conditions:   Advanced/Recurrent Breast Cancer;   Endometrial Cancer;   Ovarian Cancer
Intervention:   Drug: Temsirolimus/PLD
Sponsor:   Radboud University
Recruiting - verified March 2010

Condition:   Ovarian Cancer
Interventions:   Drug: sunitinib malate;   Other: laboratory biomarker analysis
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Not yet recruiting - verified March 2010

Conditions:   Chemotherapeutic Agent Toxicity;   Fallopian Tube Cancer;   Neurotoxicity;   Ovarian Cancer;   Pain;   Peripheral Neuropathy;   Peritoneal Cavity Cancer
Interventions:   Drug: carboplatin;   Drug: glutathione;   Drug: paclitaxel;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Not yet recruiting - verified February 2010

Condition:   Ovarian Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: paclitaxel;   Drug: topotecan;   Drug: liposomal doxorubicin
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Conditions:   Kidney Cancer;   Head and Neck Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Esophageal Cancer;   Gliomas
Intervention:   Drug: 177Lu-J591
Sponsor:   Weill Medical College of Cornell University
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Biological: adoptive immunotherapy;   Biological: alemtuzumab;   Biological: in vitro-treated peripheral blood lymphocyte therapy;   Drug: foscarnet sodium;   Drug: ganciclovir;   Genetic: polymerase chain reaction;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: infection prophylaxis and management;   Procedure: peripheral blood stem cell transplantation;   Procedure: standard follow-up care;   Radiation: radiation therapy
Sponsor:   University Hospital Birmingham
Recruiting - verified September 2009

Conditions:   Polycystic Ovary Syndrome;   Miscarriage;   Infertility;   Toxemia;   Gestational Diabetes
Intervention:   Drug: metformin
Sponsors:   University of Oulu;   University of Eastern Finland;   Helsinki University;   University of Tampere;   University of Turku
Completed - verified October 2009

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Ovarian Cancer
Intervention:   Procedure: DCE-MRI scans
Sponsor:   Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Dietary Supplement: CAM nutritional therapy;   Dietary Supplement: Lactobacillus rhamnosus GG
Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
Not yet recruiting - verified July 2009

Condition:   Tumors
Intervention:   Drug: PKI-587
Sponsor:   Wyeth
Recruiting - verified March 2010

Condition:   Ovarian Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: paclitaxel;   Drug: carboplatin
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Conditions:   Solid Tumors;   Cancer
Interventions:   Drug: XL184;   Drug: Placebo;   Drug: XL184
Sponsor:   Exelixis
Recruiting - verified February 2010

Condition:   Cancer
Interventions:   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Polycystic Ovary Syndrome;   Insulin Resistance
Interventions:   Dietary Supplement: Cinnamon Supplementation;   Dietary Supplement: Placebo (wheat flour)
Sponsor:   Pennington Biomedical Research Center
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: medical chart review;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: evaluation of cancer risk factors
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2009

Condition:   Ovarian Neoplasms
Interventions:   Biological: IMC-3G3;   Drug: liposomal doxorubicin
Sponsor:   ImClone LLC
Recruiting - verified February 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Other: laboratory biomarker analysis
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nausea and Vomiting;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: medical chart review
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Genetic: proteomic profiling;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified October 2008

Condition:   Solid Tumor
Interventions:   Drug: ABT-263;   Drug: paclitaxel;   Drug: Carboplatin
Sponsors:   Abbott;   Genentech
Recruiting - verified January 2010

Conditions:   Breast Cancer;   Non-small Cell Lung Cancer;   Ovarian Cancer;   Small Cell Lung Cancer
Intervention:  
Sponsor:   Amgen
Recruiting - verified March 2010

Conditions:   Ovarian Cancer;   Endometrial Cancer
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: docetaxel;   Drug: vandetanib
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Not yet recruiting - verified March 2010

Condition:   Cancer
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Other: immunological diagnostic method;   Other: physiologic testing
Sponsors:   Wake Forest University;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Condition:   Cancer
Interventions:   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Procedure: allogeneic bone marrow transplantation
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cancer;   Uterine Cancer;   Vaginal Cancer;   Vulvar Cancer
Intervention:   Behavioral: online platform "STAR" (Symptom Tracking and Reporting for Patients)
Sponsors:   Memorial Sloan-Kettering Cancer Center;   National Institutes of Health (NIH)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Genetic: DNA analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Carcinoma
Interventions:   Drug: Pazopanib;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Ovarian Cancer
Interventions:   Drug: VANDETANIB;   Drug: pegliposomal doxorubicin
Sponsors:   AstraZeneca;   AGO Ovarian Cancer Group Germany
Terminated - verified March 2010

Condition:   Cancer
Interventions:   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: assessment of therapy complications;   Procedure: magnetic resonance imaging
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Conditions:   Epithelial Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Intervention:   Other: Enteral feeding
Sponsor:   Queensland Centre for Gynaecological Cancer
Recruiting - verified February 2010

Condition:   Ovarian Cancer
Interventions:   Drug: MORAb-003 (farletuzumab);   Drug: MORAb-003 (farletuzumab);   Drug: 0.9% Saline
Sponsor:   Morphotek
Recruiting - verified October 2009

Conditions:   Ovarian Neoplasms;   Pancreatic Neoplasms;   Colorectal Neoplasms;   Head and Neck Neoplasms;   Lung Neoplasms
Intervention:   Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Sponsor:   Centocor, Inc.
Recruiting - verified February 2010

Conditions:   Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Ovarian Cancer;   Sarcoma;   Vaginal Cancer;   Vulvar Cancer
Interventions:   Drug: topotecan hydrochloride;   Other: pharmacological study
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Other: educational intervention;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: survey administration;   Procedure: psychosocial assessment and care;   Procedure: stress management therapy;   Procedure: support group therapy
Sponsors:   University of Colorado, Denver;   National Cancer Institute (NCI)
Recruiting - verified January 2009

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nausea and Vomiting;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Drug: ondansetron hydrochloride;   Other: survey administration;   Procedure: autologous hematopoietic stem cell transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Conditions:   Endometrial Cancer;   Kidney Cancer;   Metastatic Cancer;   Ovarian Cancer;   Peripheral Nervous System Neoplasm;   Sarcoma;   Small Intestine Cancer
Interventions:   Drug: pazopanib hydrochloride;   Other: placebo
Sponsor:   European Organization for Research and Treatment of Cancer
Active, not recruiting - verified March 2010

Condition:   Ovarian Neoplasms
Interventions:   Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting - verified February 2010

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Kidney Cancer;   Liver Cancer;   Lymphoma;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: carboplatin;   Drug: dasatinib;   Drug: etoposide phosphate;   Drug: ifosfamide;   Genetic: microarray analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Psychosocial Effects of Cancer and Its Treatment;   Sarcoma
Interventions:   Other: educational intervention;   Other: informational intervention;   Other: internet-based intervention;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Other: survey administration;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment;   Procedure: standard follow-up care
Sponsors:   Tufts Medical Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Other: internet-based intervention;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: fatigue assessment and management;   Procedure: management of therapy complications;   Procedure: psychosocial assessment and care
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Conditions:   Cancer;   Carcinoma;   Fallopian Tube Cancer;   Gynecological Malignancies;   Metastases;   Oncology;   Ovarian Cancer;   Solid Tumors;   Tumors
Interventions:   Drug: Part 2, Cohort A: AMG 386 MTD Part 1 + Liposomal doxorubicin;   Drug: B1: AMG 386 10 mg/kg + Topotecan;   Drug: B2: AMG 386 3mg/kg + Topotecan;   Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin;   Drug: A2: AMG 386 3mg/kg + Liposomal doxorubicin;   Drug: Part 2, Cohort B: AMG 386 MTD part 1 + Topotecan
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Ovarian Cancer
Interventions:   Drug: AZD2281;   Drug: matching placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified March 2010

Conditions:   Prostate Cancer;   Ovarian Cancer
Interventions:   Drug: Sagopilone 16 mg/m2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid;   Drug: Sagopilone 16 mg/m2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
Sponsor:   Bayer
Active, not recruiting - verified February 2010

Condition:   Ovarian Cancer
Intervention:   Biological: bevacizumab
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Solid Tumors;   Ovarian Neoplasms;   Prostate Cancer
Interventions:   Drug: Comparator: MK4827 (PARP inhibitor);   Drug: Comparator: MK4827 (PARP Inhibitor)
Sponsor:   Merck
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Biological: cytomegalovirus IE-1-specific cytotoxic T lymphocytes;   Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes;   Biological: therapeutic allogeneic lymphocytes;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunological diagnostic method;   Other: laboratory biomarker analysis
Sponsors:   Milton S. Hershey Medical Center;   National Cancer Institute (NCI)
Recruiting - verified December 2008

Conditions:   Renal Cell Carcinoma;   Non-small Cell Lung Cancer;   Malignant Melanoma;   Epithelial Ovarian Cancer;   Colorectal Adenocarcinoma
Intervention:   Biological: MDX-1105
Sponsor:   Bristol-Myers Squibb
Recruiting - verified March 2010

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Intervention:   Biological: IMC-1121B
Sponsor:   ImClone LLC
Active, not recruiting - verified February 2010

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Liver Cancer;   Neuroblastoma;   Ototoxicity;   Ovarian Cancer;   Sarcoma
Interventions:   Drug: sodium thiosulfate;   Procedure: examination
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Ovarian Cyst
Interventions:   Procedure: Laparoscopic ovarian cystectomy using bipolar;   Procedure: Laparoscopic ovarian cystectomy using ultrasonic scalpel;   Procedure: Laparoscopic ovarian cystectomy using suture
Sponsors:   Shandong Provincial Hospital;   Shandong University
Completed - verified May 2008

Conditions:   Ovarian Carcinoma;   Breast Cancer
Intervention:   Drug: AZD2281
Sponsors:   AstraZeneca;   British Columbia Cancer Agency
Active, not recruiting - verified March 2010

Condition:   Cancer
Interventions:   Drug: imatinib mesylate;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: confocal microscopy;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: biopsy
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions:   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
Sponsor:   Federation Nationale des Centres de Lutte Contre le Cancer
Recruiting - verified February 2010

Condition:   Adenocarcinoma of the Ovary
Intervention:   Biological: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
Sponsor:   AVAX Technologies
Recruiting - verified March 2010

Condition:   Polycystic Ovary Syndrome
Interventions:   Drug: Sibutramine (Meridia) and Lifestyle Intervention with exercise and diet;   Drug: Loestrin 1/20;   Drug: Sibutramine (Meridia) and Loestrin 1/20
Sponsors:   Penn State University;   University of Pennsylvania
Active, not recruiting - verified September 2009

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: medical chart review
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified January 2010

Conditions:   Breast Cancer;   Cognitive/Functional Effects;   Fatigue;   Psychosocial Effects of Cancer and Its Treatment;   Sleep Disorders
Interventions:   Procedure: assessment of therapy complications;   Procedure: cognitive assessment;   Procedure: fatigue assessment and management;   Procedure: psychosocial assessment and care
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Australian New Zealand Breast Cancer Trials Group;   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Ovarian, Fallopian or Primary Peritoneal Cancer.
Intervention:   Drug: Alemtuzumab
Sponsor:   University of Michigan Cancer Center
Recruiting - verified March 2010

Condition:   Ovarian Neoplasms
Interventions:   Drug: AZD2281;   Drug: Liposomal Doxorubicin;   Drug: AZD2281
Sponsor:   AstraZeneca
Active, not recruiting - verified March 2010

Condition:   Cancer
Interventions:   Drug: montelukast sodium;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified August 2008

Condition:   Ovarian Cancer
Intervention:   Drug: Fulvestrant
Sponsor:   Masonic Cancer Center, University of Minnesota
Completed - verified March 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Iron Overload;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Intervention:   Drug: deferasirox
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Active, not recruiting - verified August 2009

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Biological: wild-type reovirus
Sponsors:   Arthur G. James Cancer Hospital & Richard J. Solove Research Institute;   National Cancer Institute (NCI)
Recruiting - verified December 2008

Condition:   Cancer
Interventions:   Biological: rituximab;   Drug: cyclosporine;   Drug: methylprednisolone;   Drug: prednisone;   Drug: tacrolimus
Sponsor:   Baylor College of Medicine
Completed - verified June 2009

Condition:   Cancer
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: rituximab;   Drug: clofarabine;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified October 2008

Condition:   Cancer
Interventions:   Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes;   Genetic: polymerase chain reaction;   Other: immunological diagnostic method;   Procedure: adjuvant therapy
Sponsor:   Baylor College of Medicine
Recruiting - verified June 2009

Condition:   Breast Cancer
Intervention:  
Sponsor:   University of Michigan Cancer Center
Active, not recruiting - verified February 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: docetaxel;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Intervention:   Biological: therapeutic allogeneic lymphocytes
Sponsor:   Asan Medical Center
Completed - verified January 2008

Condition:   Polycystic Ovarian Syndrome
Interventions:   Dietary Supplement: Flax Seed Oil;   Dietary Supplement: Fish Oil;   Dietary Supplement: Soybean Oil
Sponsors:   University of California, Davis;   National Institutes of Health (NIH);   National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified October 2008

Conditions:   Prostate Cancer;   Breast Cancer;   Ovarian Cancer;   Lung Cancer;   Gastric Cancer
Intervention:   Drug: Docetaxel plus lonafarnib
Sponsor:   Schering-Plough
Recruiting - verified March 2010

Condition:   Polycystic Ovarian Syndrome
Intervention:   Other: In-vitro maturation oocytes
Sponsor:   Hillel Yaffe Medical Center
Completed - verified March 2010

Condition:   Ovarian Cancer
Interventions:   Biological: Sorafenib;   Drug: Topotecan
Sponsors:   Hoosier Oncology Group;   Bayer
Terminated - verified February 2010

Condition:   Advanced Solid Tumors
Intervention:   Drug: Epofolate
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified February 2010

Conditions:   Non-hematologic Malignancies;   Metastatic Melanoma;   Breast Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Hepatocellular Carcinoma
Interventions:   Drug: ABT-888;   Drug: Temozolomide
Sponsor:   Abbott
Active, not recruiting - verified December 2009

Condition:   Advanced Solid Tumors
Intervention:   Drug: Epofolate
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified February 2010

Condition:   Cancer
Interventions:   Drug: fentanyl sublingual spray;   Other: questionnaire administration
Sponsor:   Insys Therapeutics Inc
Recruiting - verified October 2008

Conditions:   Ovarian Neoplasms;   BRCA1 Protein;   BRCA2 Protein
Intervention:   Drug: KU-0059436 (AZD2281)(PARP inhibitor)
Sponsors:   AstraZeneca;   KuDOS Pharmaceuticals Limited
Active, not recruiting - verified March 2010

Condition:   Ovarian Cancer
Interventions:   Behavioral: Interview;   Behavioral: Questionnaire
Sponsor:   M.D. Anderson Cancer Center
Active, not recruiting - verified February 2010

Condition:   Colon Cancer
Intervention:   Behavioral: Questionnaire
Sponsor:   M.D. Anderson Cancer Center
Active, not recruiting - verified March 2010

Conditions:   Hereditary Nonpolyposis Colorectal Cancer;   Lynch Syndrome
Intervention:   Behavioral: Questionnaire
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Conditions:   Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention:   Behavioral: Questionnaire
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Conditions:   Ovarian Cancer;   Peritoneum Tumors
Intervention:   Behavioral: Data Collection
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Conditions:   Ovarian Cancer;   Primary Peritoneal Cancer
Interventions:   Drug: pemetrexed;   Drug: carboplatin
Sponsor:   Eli Lilly and Company
Completed - verified March 2010

Condition:   Cancer
Interventions:   Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis
Sponsor:   Milton S. Hershey Medical Center
Recruiting - verified October 2007

Condition:   Endometrial Cancer
Intervention:   Behavioral: Questionnaire
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Conditions:   Bladder Cancer;   Breast Cancer;   Kidney Cancer;   Lung Cancer;   Ovarian Cancer;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: custirsen sodium;   Drug: docetaxel;   Other: pharmacological study
Sponsor:   NCIC Clinical Trials Group
Completed - verified March 2010

Condition:   Neoplasms
Interventions:   Drug: OGX-427;   Drug: Docetaxel
Sponsor:   OncoGenex Technologies
Recruiting - verified February 2010

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: ifosfamide;   Drug: paclitaxel
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Ovarian Cancer
Interventions:   Drug: levonorgestrel;   Other: placebo
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Genetic: polymerase chain reaction;   Other: bronchoalveolar lavage;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Procedure: bronchoscopy;   Procedure: management of therapy complications
Sponsor:   St. Bartholomew's Hospital
Recruiting - verified September 2007

Conditions:   Brain and Central Nervous System Tumors;   Intraocular Melanoma;   Lung Cancer;   Melanoma (Skin);   Metastatic Cancer;   Neuroblastoma;   Ovarian Cancer;   Retinoblastoma;   Sarcoma;   Small Intestine Cancer
Interventions:   Other: immunologic technique;   Other: pharmacological study;   Radiation: iodine I 131 monoclonal antibody 3F8
Sponsor:   Memorial Sloan-Kettering Cancer Center
Recruiting - verified July 2009

Conditions:   Breast Cancer;   Ovarian Cancer
Interventions:   Biological: pNGVL3-hICD vaccine;   Biological: sargramostim;   Genetic: protein expression analysis;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: immunologic technique;   Procedure: adjuvant therapy;   Procedure: biopsy
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Condition:   Polycystic Ovary Syndrome
Interventions:   Drug: Metformin;   Drug: Placebo
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital
Completed - verified March 2010

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Intervention:   Drug: LY573636
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Other: counseling intervention;   Other: educational intervention;   Procedure: psychosocial assessment and care
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 2008

Condition:   Polycystic Ovary Syndrome
Intervention:  
Sponsor:   National Institute of Environmental Health Sciences (NIEHS)
Completed - verified March 2010

Condition:   Hematopoietic Stem Cell Transplantation
Interventions:   Drug: Leuprolide Acetate;   Behavioral: Questionnaire
Sponsors:   M.D. Anderson Cancer Center;   TAP Pharmaceutical Products Inc.
Active, not recruiting - verified February 2010

Conditions:   Endometrial Cancer;   Ovarian Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: eribulin mesylate;   Drug: gemcitabine hydrochloride
Sponsors:   Princess Margaret Hospital, Canada;   National Cancer Institute (NCI)
Recruiting - verified May 2007

Conditions:   Endometrial Cancer;   Ovarian Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: temsirolimus
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Condition:   Ovarian Cancer
Intervention:   Drug: capecitabine
Sponsor:   National Cancer Institute, Naples
Completed - verified February 2010

Condition:   Ovarian Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel
Sponsor:   National Cancer Institute, Naples
Completed - verified February 2010

Condition:   Cancer
Intervention:   Drug: lithium carbonate
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Adults;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Sexual Dysfunction and Infertility;   Sexuality and Reproductive Issues;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: laboratory biomarker analysis;   Procedure: fertility assessment and management;   Procedure: management of therapy complications;   Procedure: ultrasound imaging
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Drug: sunitinib malate
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Condition:   Cancer
Interventions:   Drug: heparin;   Drug: minocycline-EDTA
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Completed - verified September 2007

Condition:   Breast Cancer
Interventions:   Biological: HER-2/neu intracellular domain protein;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: immunological diagnostic method;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Biological: denileukin diftitox
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Suspended - verified March 2010

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Kidney Cancer;   Leukemia;   Liver Cancer;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: cediranib maleate;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: magnetic resonance imaging
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified July 2009

Conditions:   Ovarian Cancer;   Merkel Cell Carcinoma;   SCLC
Intervention:   Drug: BB-10901
Sponsor:   ImmunoGen, Inc.
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Biological: graft versus host disease prophylaxis/therapy;   Genetic: fluorescence in situ hybridization;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: in vitro-treated bone marrow transplantation;   Procedure: management of therapy complications
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified March 2010

Conditions:   Cervical Cancer;   Endometrial Cancer;   Ovarian Cancer;   Vaginal Cancer;   Vulvar Cancer
Interventions:   Drug: cisplatin;   Drug: triapine;   Genetic: molecular diagnostic method;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: pharmacological study;   Radiation: brachytherapy;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Intervention:   Drug: moxifloxacin hydrochloride
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Osteoporosis;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Dietary Supplement: calcium carbonate;   Dietary Supplement: calcium citrate;   Dietary Supplement: calcium glucarate;   Dietary Supplement: cholecalciferol;   Drug: calcium gluconate;   Drug: zoledronic acid
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified October 2008

Conditions:   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer;   Stage IV Breast Cancer
Interventions:   Drug: lapatinib (GW572016);   Drug: Carboplatin;   Drug: Paclitaxel
Sponsors:   Swedish Medical Center;   GlaxoSmithKline
Active, not recruiting - verified March 2010

Condition:   Cancer
Interventions:   Other: laboratory biomarker analysis;   Other: physiologic testing;   Procedure: biopsy;   Procedure: management of therapy complications
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified September 2006

Conditions:   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Osteoporosis;   Ovarian Cancer
Interventions:   Drug: zoledronic acid;   Other: clinical observation
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Ovarian Cancer
Intervention:   Drug: CT-2106
Sponsor:   Cell Therapeutics
Completed - verified February 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nausea and Vomiting;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Drug: aprepitant;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: granisetron hydrochloride
Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Active, not recruiting - verified June 2009

Condition:   Cancer
Interventions:   Procedure: music therapy;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   National Institute of Nursing Research (NINR)
Recruiting - verified March 2010

Condition:   Ovarian Cancer
Intervention:   Drug: XL999
Sponsor:   Symphony Evolution, Inc.
Terminated - verified February 2010

Condition:   Ovarian Cancer
Intervention:   Drug: Exemestane
Sponsor:   Ottawa Hospital Research Institute
Completed - verified March 2010

Conditions:   Lung Cancer;   Metastatic Cancer;   Ovarian Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Procedure: computed tomography;   Procedure: positron emission tomography;   Radiation: 11C topotecan;   Radiation: fludeoxyglucose F 18
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Ovarian Cancer
Intervention:   Drug: Topotecan and VP16
Sponsor:   New Mexico Cancer Care Alliance
Completed - verified October 2008

Condition:   Ovarian Neoplasms
Intervention:   Procedure: removal of ovarian vessels
Sponsor:   Department of Defense
Completed - verified March 2004

Condition:   Ovary Cancer
Intervention:  
Sponsors:   Maastricht Radiation Oncology;   Maastricht University Medical Center
Withdrawn - verified March 2010

Conditions:   Cervical Cancer;   Endometrial Cancer;   Ovarian Cancer;   Vaginal Cancer
Interventions:   Drug: capecitabine;   Radiation: brachytherapy;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Condition:   Polycystic Ovary Syndrome
Interventions:   Drug: Metformin;   Drug: Placebo;   Dietary Supplement: Diet and lifestyle advices
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital
Completed - verified March 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Biological: alemtuzumab;   Drug: methylprednisolone;   Drug: tacrolimus
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: paclitaxel;   Drug: paclitaxel poliglumex;   Other: clinical observation
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Intervention:   Drug: caspofungin acetate
Sponsor:   European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009

Conditions:   Lung Cancer;   Breast Cancer;   Bladder Cancer;   Ovarian Cancer;   Pancreatic Cancer
Interventions:   Drug: AMG 706;   Biological: Panitumumab;   Drug: Gemcitabine/Cisplatin
Sponsor:   Amgen
Terminated - verified February 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: sorafenib tosylate
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: pentostatin
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: docetaxel;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: paclitaxel;   Procedure: adjuvant therapy
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Drug: itraconazole;   Drug: voriconazole
Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified April 2005

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Intervention:   Drug: pentostatin
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
Active, not recruiting - verified March 2008

Condition:   Cancer
Intervention:   Drug: forodesine hydrochloride
Sponsor:   BioCryst Pharmaceuticals
Completed - verified July 2004

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor
Intervention:   Biological: therapeutic allogeneic lymphocytes
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Condition:   Neoplasms
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 2009

Conditions:   Breast Cancer;   Menopausal Symptoms;   Sexual Dysfunction and Infertility
Interventions:   Drug: cyclophosphamide;   Drug: goserelin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   International Breast Cancer Study Group
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
Intervention:   Drug: ravuconazole
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified July 2004

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate;   Drug: triptorelin;   Procedure: oophorectomy;   Radiation: radiation therapy
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Procedure: acupuncture therapy;   Procedure: management of therapy complications;   Procedure: pain therapy
Sponsor:   National Cancer Institute (NCI)
Completed - verified April 2004

Conditions:   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Drug: irofulven
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Completed - verified April 2008

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: cisplatin;   Drug: etoposide;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Drug: docetaxel;   Drug: thalidomide
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Oral Complications;   Ovarian Cancer;   Pain;   Sarcoma
Interventions:   Procedure: management of therapy complications;   Procedure: pain therapy
Sponsor:   Medical College of Wisconsin
Recruiting - verified June 2009

Condition:   Healthy
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified October 2009

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: carboplatin;   Drug: erlotinib hydrochloride
Sponsor:   NCIC Clinical Trials Group
Completed - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Drug: topotecan hydrochloride
Sponsors:   NCIC Clinical Trials Group;   European Organization for Research and Treatment of Cancer
Active, not recruiting - verified November 2005

Conditions:   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Drug: fenretinide
Sponsors:   California Cancer Consortium;   National Cancer Institute (NCI)
Completed - verified April 2004

Conditions:   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Drug: ixabepilone
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Completed - verified July 2006

Conditions:   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Drug: bortezomib
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Completed - verified September 2005

Conditions:   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Biological: bevacizumab
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Completed - verified September 2004

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: filgrastim;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: paclitaxel;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy
Sponsor:   National Cancer Institute (NCI)
Completed - verified January 2007

Conditions:   Brain and Central Nervous System Tumors;   Breast Cancer;   Kidney Cancer;   Lung Cancer;   Lymphoma;   Melanoma (Skin);   Ovarian Cancer;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: carboxyamidotriazole;   Drug: paclitaxel
Sponsor:   National Cancer Institute (NCI)
Completed - verified August 2006

Conditions:   Breast Cancer;   Kidney Cancer;   Lung Cancer;   Ovarian Cancer;   Sarcoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Biological: aldesleukin;   Biological: recombinant interleukin-12
Sponsor:   National Cancer Institute (NCI)
Completed - verified February 2007

Conditions:   Breast Cancer;   Osteoporosis
Interventions:   Dietary Supplement: calcium carbonate;   Dietary Supplement: calcium citrate;   Dietary Supplement: cholecalciferol;   Drug: calcium gluconate;   Drug: zoledronic acid;   Procedure: adjuvant therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Completed - verified March 2006

Condition:   Cancer
Intervention:   Drug: entinostat
Sponsor:   National Cancer Institute (NCI)
Completed - verified February 2007

Condition:   Cancer
Interventions:   Drug: dexamethasone;   Drug: ondansetron;   Procedure: quality-of-life assessment
Sponsor:   NCIC Clinical Trials Group
Completed - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Drug: lurtotecan liposome
Sponsor:   NCIC Clinical Trials Group
Completed - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: bryostatin 1;   Drug: cisplatin
Sponsors:   California Cancer Consortium;   National Cancer Institute (NCI)
Completed - verified March 2003

Condition:   Cancer
Interventions:   Drug: caspofungin acetate;   Drug: liposomal amphotericin B
Sponsors:   Memorial Sloan-Kettering Cancer Center;   National Cancer Institute (NCI)
Completed - verified December 2009

Condition:   Ovarian Cancer
Intervention:   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Head and Neck Cancer;   Lung Cancer;   Ovarian Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: cisplatin;   Drug: lurtotecan liposome
Sponsor:   NCIC Clinical Trials Group
Completed - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Breast Cancer;   Extragonadal Germ Cell Tumor;   Infection;   Lung Cancer;   Lymphoma;   Ovarian Cancer;   Small Intestine Cancer;   Testicular Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Drug: levofloxacin
Sponsor:   Cancer Research Campaign Clinical Trials Centre
Active, not recruiting - verified July 2002

Conditions:   Lymphoma;   Ovarian Cancer;   Sarcoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Drug: tanespimycin
Sponsors:   University of Pittsburgh;   National Cancer Institute (NCI)
Completed - verified February 2005

Condition:   Ovarian Cancer
Intervention:   Drug: ISIS 5132
Sponsor:   NCIC Clinical Trials Group
Completed - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Drug: chemotherapy
Sponsors:   Medical Research Council;   European Organization for Research and Treatment of Cancer
Active, not recruiting - verified September 2005

Conditions:   Colorectal Cancer;   Lung Cancer;   Ovarian Cancer;   Prostate Cancer
Interventions:   Other: screening questionnaire administration;   Procedure: long-term screening
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Condition:   Cancer
Intervention:   Drug: liposomal amphotericin B
Sponsor:   European Organization for Research and Treatment of Cancer
Active, not recruiting - verified March 2000

Condition:   Cancer
Interventions:   Biological: graft versus host disease prophylaxis/therapy;   Procedure: allogeneic bone marrow transplantation
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified March 2010

Condition:   Cancer
Intervention:   Procedure: infection prophylaxis and management
Sponsor:   Fred Hutchinson Cancer Research Center
Completed - verified March 2010